The collective results demonstrated that ZBTB16 exerts significant tumor suppressor effects through upregulation of ZBTB28 and downregulation of BCL6 and supported its identity as a prognostic biomarker to improve treatment outcomes of breast cancer. This evidence concerns the gene BCL6B and breast carcinoma.